Cargando…
Cancer Stem Cells /
Cancer Stem Cells, Volume 141 in the Advances in Cancer Research series, presents the latest release in this ongoing, well-regarded serial that provides invaluable information on the exciting and fast-moving field of cancer research. Topics covered in this new release include SIX-EYA-DACH network co...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Cambridge, MA :
Academic Press,
2019.
|
| Edición: | First edition. |
| Colección: | Advances in cancer research ;
v. 141. |
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Front Cover; Cancer Stem Cells; Copyright; Contents; Contributors; Preface; References; Chapter One: Regulation of cancer stem cell properties by SIX1, a member of the PAX-SIX-EYA-DACH network; 1. Introduction; 2. Cancer stem cells (CSCs); 3. SIX1 and CSCs; 4. Sustained proliferative signaling; 5. Evading growth suppressors; 6. Enabling replicative immortality; 7. Resisting cell death; 8. Genome instability and mutation; 9. Deregulating cellular energetics; 10. Inducing angiogenesis; 11. Regulation of SIX1 expression; 12. SIX1 clinical significance; 13. EYA; 14. DACH; 15. Concluding remarks.
- AcknowledgmentsConflict of interest; References; Chapter Two: Dormancy and cancer stem cells: An enigma for cancer therapeutic targeting; 1. Introduction; 1.1. Classification of cancer stem cells and non-stem cancer cells based on dormancy; 1.2. Different forms of dormancy; 1.3. Dormancy, metastasis, CSCs, heterogeneity, plasticity and recurrence; 2. Molecular mechanisms of dormancy; 2.1. Effect of different niches on dormancy; 2.1.1. Bone marrow stem cell niche; 2.1.2. Perivascular niche; 2.1.3. CSC niche; 2.1.4. Metastatic niche; 2.2. Angiogenic switch; 2.3. Microenvironmental factors.
- 2.4. Epigenetics in dormancy2.5. Oncogene addiction; 2.6. Biophysical regulators of dormancy; 2.7. Biomarkers of tumor dormancy; 2.8. Senescence and dormancy; 2.9. Autophagy and dormancy; 3. Therapy and dormancy; 4. Expert opinion; Acknowledgments; Conflict of interest; References; Further reading; Chapter Three: Clonal hematopoiesis: Pre-cancer PLUS; 1. Introduction; 2. CH vs CHIP; 3. CHIP vs MDS; 4. CH from stochastic processes; 5. CH from selection; 5.1. Processes of aging; 5.2. Cytotoxic therapy; 5.3. Immune-mediated; 6. Evolution of evidence for CH in asymptomatic individuals.
- 7. Epidemiology of CH8. CH from candidate drivers; 9. CH from unknown drivers; 10. Germline predisposition to CH; 11. CH and hematologic malignancy; 12. CHIP and CVD risk; 13. CH in other conditions; 14. Conclusion; References; Chapter Four: Assays for functionally defined normal and malignant mammary stem cells; 1. Introduction; 2. Breast cancer stem cells: A unifying theory or an impossible hope?; 3. Evolution of functional normal and malignant stem cell assays; 4. Mammary repopulating unit cell assay to quantify normal mammary stem cells.
- 5. Mammary tumor initiating cell assay to measure breast cancer stem cells5.1. Important considerations; 6. DNA barcoding as a method to study clonal dynamics of normal and malignant mammary stem cells; 6.1. Factors affecting barcoding experiments; 6.1.1. Barcode design; 6.1.2. Barcode diversity; 6.1.3. Viral transduction; 6.1.4. Barcode analysis; 7. Conclusions; 8. Future perspectives; Acknowledgments; References; Chapter Five: Hypoxia-inducible factors promote breast cancer stem cell specification and maintenance in response to hypo ... ; 1. Introduction; 1.1. Breast cancer stem cells.